The largest database of trusted experimental protocols

Hematrue hematology analyzer

Manufactured by Heska
Sourced in United States

The HemaTrue Hematology Analyzer is a compact, automated device designed for rapid and accurate analysis of blood samples. It provides a comprehensive assessment of various blood parameters, including red blood cell count, white blood cell count, and platelet count. The HemaTrue Hematology Analyzer is a reliable tool for routine clinical use, delivering consistent and dependable results.

Automatically generated - may contain errors

17 protocols using hematrue hematology analyzer

1

Hematopoietic Stem Cell Therapy Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eight- to 10-week old female C57BL/6J mice, weighing approximately 20 g, were injected intraperitoneally (i.p.) with PBS, SCF or S4-3a daily starting 2 days prior to sublethal total body irradiation (TBI) and continued until 7 days post-TBI, for a total of 10 days. The protein treatments were administered at 250 μg/kg. Sublethal dose of TBI at 450 Rads was given at Day 0, and complete blood count (CBC) was performed on Day 0, 7, 11, 16, 21 and 40 using Hematrue hematology analyzer (Heska). Peripheral blood samples was collected from the tail vein of mice.
+ Open protocol
+ Expand
2

Comprehensive Hematological Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Hematology analysis of blood samples was also performed in additional rats to assess for signs of immunosuppression or infection. Venous blood samples (0.2 ml) were collected in EDTA coated tubes and analyzed immediately for concentrations of platelets and red and white blood cells (HemaTrue Hematology Analyzer, Heska Corp., Loveland, CO, USA). Relative proportions of the different types of white cells were also assessed by measuring the numbers of monocytes, granulocytes and lymphocytes.
+ Open protocol
+ Expand
3

Preclinical Evaluation of HCI-2509 in PC3 Xenograft Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
All in vivo studies were approved and conducted as per the regulations of the Institutional Animal Care and Use Committee at the University of Utah. Sample size calculation accounted for an attrition rate of 10%. The power calculation was based on a two-tailed test of significance with a type I error of 0.05 and a 0.9 probability of detecting a true difference. This yielded a sample size of 10 animals per arm.
Five million PC3 cells were suspended in 50% media (RPMI) and 50% Matrigel (BD Biosciences), and then implanted in the right hind flank of female nude mice. Animals bearing tumors of adequate size (100 mm3) were randomized based on size into three cohorts of 10 animals each and dosed with either vehicle intraperitoneally (Monday, Wednesday and Friday), 40 mg kg−1 HCI-2509 intraperitoneally (Monday, Wednesday and Friday) or 40 mg kg−1 HCI-2509 orally (per os) (daily, Monday through Friday) for 3 weeks (last dose administered on Day 19). Body weight and tumor volume were measured twice weekly. Blood cell counts (hematocrit, platelet and white blood cell) were measured on days 1 and 24 using a HemaTrue Hematology Analyzer (Heska, Loveland, CO, USA).
+ Open protocol
+ Expand
4

In Vivo Xenograft Tumor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
A673, SK-N-MC or SKES1 cells were injected into the right hindflanks of nude mice at 1×106 cells or 1×106 cells or 2.5×106 cells per flank, respectively. For all xenograft studies, ten mice per condition were injected subcutaneously; therefore ten tumors were measured per group. In the SK-N-MC study, one animal perished due to an unrelated rash and was censored from analysis. Tumors were measured using digital calipers and volumes were calculated as follows: (L×W×D)/2. Treatment was initiated on day 7 after bioluminescent imaging confirmed tumor engraftment in the A673 study, while SK-N-MC and SK-ES-1 studies were initiated once tumors reached a volume of >100 mm3. Mice in each group were sacrificed once tumors reached a size limit of 2 cm3. Kaplan-Meier survival curves were plotted using GraphPad Prism. Tumor volume and body weight were recorded for all three models. Harvested tumors harvested were flash frozen, homogenized by mortar and pestle in liquid nitrogen analyzed for RNA or protein. All xenograft experiments were performed in accordance with protocol 11-11003 approved by the University of Utah IACUC. Blood Counts: The facial vein was identified and pierced with a lancet, blood was collected in a heparin capillary tube, and analyzed using a HemaTrue hematology analyzer (Heska).
+ Open protocol
+ Expand
5

3'3'-cGAMP Treatment in Murine CLL and MM

Check if the same lab product or an alternative is used in the 5 most similar protocols
The peripheral blood of Eμ-TCL1 mice was collected by submandibular bleeding. Eμ-TCL1 Mice with high CLL burden were identified by measuring lymphocyte numbers using a HemaTrue Hematology Analyzer (HESKA) and examining the percentage of CLL cells in PBMCs. These mice received intraperitoneal injections with 3′3′-cGAMP (10 mg/kg) dissolved in 20% DMSO in PBS on Days 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18 and 19. Lymphocyte numbers in their peripheral blood were measured on Days 7, 14 and 21. KaLwRij mice were intravenously injected with 5 × 106 5TGM1 or 5TGM1 STING-ZFN multiple myeloma cells on D0; intraperitoneally injected with 3′3′-cGAMP (10 mg/kg) on Days 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20 and 21; and monitored for survival. Immunodeficient NSG mice were subcutaneously injected with 5 × 106 5TGM1 multiple myeloma cells on D0; intraperitoneally injected with 3′3′-cGAMP (10 mg/kg) on Days 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18 and 19; and monitored for the size of tumor and weight at the indicated times.
+ Open protocol
+ Expand
6

Hematologic Profiling of Anesthetized Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols
At endpoint, each anesthetized rat underwent antemortem cardiac puncture to collect blood for hematologic analyses (CBC; complete blood count with differential) to quantify the following thirteen parameters associated with either systemic inflammation/infection or anemia status: white blood cell count (WBC), lymphocyte concentration (Lymph), monocyte concentration (Mono), granulocyte concentration (Gran), hematocrit (HCT), mean cell volume of red blood cells (MCV), red blood cell distribution width (RDWa), hemoglobin concentration (Hgb), mean cell hemoglobin concentration (MCHC), mean cell hemoglobin (MCH), red blood cell count (RBC), total platelet count (PLT), and mean and platelet volume (MPV) (HemaTrue Hematology Analyzer, Heska, Loveland, CO, USA). Blood was collected in vacutainer tubes with Ethylenediaminetetraacetic acid (EDTA) and immediately processed. A one-way ANOVA model was used to compare hematologic parameters between treatment groups, with α = 0.05.
+ Open protocol
+ Expand
7

Evaluating Long-Term HS-106 Effects in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 10

Female FVB/J mice aged to 10-12 weeks (Jackson Labs, Maine) were intraperitonealy (IP) injected twice weekly with HS-106 at the described doses. Mice were monitored for signs of toxicity by standard Mouse Phase 1 Unit (M1P1U; https://www.med.unc.edu/mousephase1) protocols and approved by UNC-CH IACUC. Prior to end of the study 150 μl of whole blood was drawn via submandibular bleed and used to determine hematology values, liver, and kidney functions by HemaTrue Hematology Analyzer (HESKA, Loveland, Colo., USA) and VITROS® 350 Chemistry System (J&J, New Brunswick, N.J.) according to manufacturer protocols. To determine the long term effects of HS-106 on mice weight, female FVB/J mice aged 12-16 weeks were treated with the indicated concentrations of HS-106 twice weekly by IP injection for 60 days. Mice body mass was assessed weekly, and mice were observed daily for signs of toxicity (e.g. labored breathing and hunched posture).

+ Open protocol
+ Expand
8

Assessing Mouse Hematology and Colon Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Following puncture of either the facial vein or the retro-orbital venous sinus, WT, Gab2−/−, Gab3−/−, and Gab2/3−/− mice peripheral blood was collected in a heparinized capillary tube (Thermo Fisher Scientific, Norcross, GA). Mouse hematology was determined using a HemaTrue Hematology Analyzer (Heska, Loveland, CO). Mice showing loss of 25% body weight, major organ failure, rectal prolapse, hind limb paralysis, or clinical or behavioral signs described above for more than 24 h after appropriate intervention (and no response) were euthanized by the CO2 method according to the IACUC protocol. Macroscopic colon inflammation score (0–9): Colon weight was scored as follows: 200–275 mg = 0; 276–350 mg = 1; 351–425 mg = 2; 426–550 mg = 3. Colon thickness was scored as follows: none = 0; mild = 1; moderate = 2; severe = 3. Stool consistency was scored as follows: hard = 0; mostly hard but some soft = 1; mostly soft but some hard = 2; diarrhea = 3.
+ Open protocol
+ Expand
9

Murine Blood Collection and CBC Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood (20 ul) was obtained in an EDTA coated capillary tube following tail snip. CBC were determined using a HemaTrue Hematology Analyzer (Heska Corporation, Loveland, CO) at the Mouse Physiology Phenotyping Center at Case Western Reserve University.
+ Open protocol
+ Expand
10

Blood Collection and CBC Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
20uL of blood was obtained in an EDTA coated capillary tube following tail snip. CBC were determined using a HemaTrue Hematology Analyzer (Heska Corporation, Loveland, CO) at the MPPC (Mouse Physiology Phenotyping Center) at Case Western Reserve University.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!